Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 5, 2015, Pages E478-E486

  Tu, Xiaolin ^a   Delgado Calle, Jesus ^a   Condon, Keith W ^a   Maycas, Marta ^a   Zhang, Huajia ^a   Carlesso, Nadia ^a   Taketo, Makoto M ^b   Burr, David B ^a   Plotkin, Lilian I ^a   Bellido, Teresita ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Beta catenin; Bone anabolism; Canonical Wnt; Notch signaling; Osteocytes

Indexed keywords

ALKALINE PHOSPHATASE; BETA CATENIN; COLONY STIMULATING FACTOR 1; CYTOKINE; NOTCH RECEPTOR; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE MATRIX; BONE MINERAL; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GENE EXPRESSION; GENETIC MARKER; LEUKEMIA; MALE; MOUSE; NEWBORN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PERINATAL DEATH; PERIOSTEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TRABECULAR BONE; WNT SIGNALING PATHWAY; ANIMAL; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; BETA CATENIN; BONE AND BONES; BONE DENSITY; MICE; MICE, TRANSGENIC; OSTEOCYTES; WNT SIGNALING PATHWAY;

EID: 84922309760     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1409857112     Document Type: Article

References (51)

1. Cauley JA (2013) Public health impact of osteoporosis. J Gerontol A Biol Sci Med Sci 68(10):1243-1251.
2. Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26(2):229-238.
3. Bellido T (2014) Osteocyte-driven bone remodeling. Calcif Tissue Int 94(1):25-34.
4. Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med 19(2):179-192.
5. Wodarz A, Nusse R (1998) Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14:59-88.
6. Gong Y, et al.; Osteoporosis-Pseudoglioma Syndrome Collaborative Group (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107(4):513-523.
7. Boyden LM, et al. (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346(20):1513-1521.
8. Little RD, et al. (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70(1):11-19.
9. Hu H, et al. (2005) Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132(1):49-60.
10. Day TF, Guo X, Garrett-Beal L, Yang Y (2005) Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 8(5):739-750.
11. Hill TP, Spöter D, Taketo MM, Birchmeier W, Hartmann C (2005) Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 8(5):727-738.
12. Rodda SJ, McMahon AP (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133(16):3231-3244.
13. Glass DA, 2nd, et al. (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8(5):751-764.
14. Holmen SL, et al. (2005) Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280(22):21162-21168.
15. Kramer I, et al. (2010) Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 30(12):3071-3085.
16. Kode A, et al. (2014) Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature 506(7487):240-244.
17. Bellido T, et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146(11):4577-4583.
18. O'Brien CA, et al. (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3(8):e2942.
19. Rhee Y, et al. (2011) PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res 26(5):1035-1046.
20. Robling AG, et al. (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283(9):5866-5875.
21. Robling AG, et al. (2011) Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology 152(8):2963-2975.
22. Tu X, et al. (2012) Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone 50(1):209-217.
23. Balemans W, et al. (2002) Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39(2):91-97.
24. Loots GG, et al. (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15(7):928-935.
25. Balemans W, et al. (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10(5):537-543.
26. Brunkow ME, et al. (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68(3):577-589.
27. Balemans W, et al. (2007) Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res 22(5):708-716.
28. Balemans W, et al. (2008) The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int 82(6):445-453.
29. Ota K, et al. (2013) Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem 114(8):1901-1907.
30. Rodilla V, et al. (2009) Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA 106(15):6315-6320.
31. Estrach S, Ambler CA, Lo Celso C, Hozumi K, Watt FM(2006) Jagged 1 is a beta-catenin target gene required for ectopic hair follicle formation in adult epidermis. Development 133(22):4427-4438.
32. Galceran J, Sustmann C, Hsu SC, Folberth S, Grosschedl R (2004) LEF1-mediated regulation of Delta-like1 links Wnt and Notch signaling in somitogenesis. Genes Dev 18(22):2718-2723.
33. Hofmann M, et al. (2004) WNT signaling, in synergy with T/TBX6, controls Notch signaling by regulating Dll1 expression in the presomitic mesoderm of mouse embryos. Genes Dev 18(22):2712-2717.
34. Chen J, Long F (2013) β-catenin promotes bone formation and suppresses bone resorption in postnatal growing mice. J Bone Miner Res 28(5):1160-1169.
35. Javaheri B, et al. (2014) Deletion of a single β-catenin allele in osteocytes abolishes the bone anabolic response to loading. J Bone Miner Res 29(3):705-715.
36. Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747-783.
37. Wijenayaka AR, et al. (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6(10):e25900.
38. Ben-awadh AN, et al. (2014) Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology 155(8):2797-2809.
39. Rhee Y, et al. (2013) Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes. J Biol Chem 288(41):29809-29820.
40. Rhee Y, et al. (2011) Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49(4):636-643.
41. Hilton MJ, et al. (2008) Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 14(3):306-314.
42. Tu X, et al. (2012) Physiological notch signaling maintains bone homeostasis via RBPjk and Hey upstream of NFATc1. PLoS Genet 8(3):e1002577.
43. Engin F, et al. (2008) Dimorphic effects of Notch signaling in bone homeostasis. Nat Med 14(3):299-305.
44. Tao J, et al. (2010) Osteosclerosis owing to Notch gain of function is solely Rbpj-dependent. J Bone Miner Res 25(10):2175-2183.
45. Canalis E, Parker K, Feng JQ, Zanotti S (2013) Osteoblast lineage-specific effects of notch activation in the skeleton. Endocrinology 154(2):623-634.
46. Stolina M, et al. (2014) Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone 67:305-313.
47. Bivi N, et al. (2012) Cell autonomous requirement of connexin 43 for osteocyte survival: Consequences for endocortical resorption and periosteal bone formation. J Bone Miner Res 27(2):374-389.
48. Harada N, et al. (1999) Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 18(21):5931-5942.
49. Sakata T, et al. (2004) Skeletal unloading induces resistance to insulin-like growth factor-I (IGF-I) by inhibiting activation of the IGF-I signaling pathways. J Bone Miner Res 19(3):436-446.
50. Hauge E, Mosekilde L, Melsen F (1999) Missing observations in bone histomorphometry on osteoporosis: Implications and suggestions for an approach. Bone 25(4):389-395.
51. Dempster DW, et al. (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2-17.